#IDSAGuidelines

NEW #IDSAGuidelines! IDSA has updated our guidelines on community-acquired pneumonia in pediatrics: www.idsociety.org/practice-guideline/commu...

#IDSAGuidelines update! We’ve updated a remark in our 2025 guidance on influenza vaccination in immunocompromised patients (bolded below).

For more information and to view the supporting rationale, visit https://bit.ly/4r2kNnr

New #IDSAGuidelines! IDSA has released updated evidence-based recommendations on administering age-appropriate Influenza and RSV vaccinations in populations with compromised immunity. www.idsociety.org/Seasonal-RTI-Vaccination...

New #IDSAGuidelines! IDSA has released updated evidence-based recommendations on the use of nirmatrelvir/ritonavir, remdesivir, and molnupiravir in adults with mild to moderate COVID-19: https://bit.ly/3W5IdtT

Updated #IDSAGuidelines! IDSA has issued two new guidelines on abatacept and infliximab for COVID-19, offering evidence-based recommendations for their use in hospitalized patients with moderate to severe disease.

View guidelines: bit.ly/2V34gT8

Updated #IDSAGuidelines! IDSA Guidelines on Histoplasmosis Treatment: Focused Update on Asymptomatic Histoplasma Pulmonary Nodules and Mild or Moderate Acute Pulmonary Histoplasmosis are out now: buff.ly/vHZV7YQ

In adults hospitalized with critical COVID-19, should #vilobelimab compared to no vilobelimab be added to standard care?

A focused update on vilobelimab is now available via #IDSAGuidelines: https://buff.ly/41C067f